The diagnostic utility of prostate biopsy is limited for prostate cancer (PCa) in the prostate-specific antigen (PSA) grey zone. This study aims to evaluate the diagnostic performance of ...

Daniel W. Lin, MD, reviews new guidance on using MRI, biomarkers, and more, to improve the detection of prostate cancer.

MRI of the prostate, combined with a blood test, can help determine if a prostate lesion is clinically significant cancer, new research suggests A new meta-analysis by investigators from Brigham and ...

Multiparametric prostate MRI (mpMRI) is being increasingly adopted for work-up of prostate cancer. For patients selected to omit biopsy, we identified factors associated with repeat MRI, eventual ...

Prostate-targeted, engineered nanoparticles made of amorphous silica are effective in killing prostate tumors directly while ...

Stockholm3, which combines prostate-specific antigen (PSA), plasma protein biomarkers, polygenic risk, and clinical factors ...

In metastatic prostate cancer, AI-facilitated quantification of metastatic burden, accurate identification of castration resistance, and prediction of treatment sensitivity and resistance are active ...

A research team at Osaka University will start an investigator-initiated clinical trial for refractory prostate cancer patients after the successful development of a new alpha-ray therapeutic agent ...

Stage 3 prostate cancer is locally advanced, with tumors extending beyond the prostate but not metastasizing distantly. Diagnosis involves the TNM system, Gleason score, PSA tests, and imaging to ...

A multimodal AI model identified a subset of men with very high-risk localized prostate cancer who derived substantial ...

Fear can take over the moment prostate cancer progresses. These questions can help caregivers replace confusion with clarity, ...

For its 2nd anniversary, Callisto DataHub offers free annotated datasets of 50 suspected lung cancer X-rays and 50 prostate cancer MRI cases for commercial use ...